Lindsay, C.R., MacPherson, I.R.J. and Cassidy, J. (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology, 5(4), pp. 421-432. (doi: 10.2217/FON.09.18)
Full text not currently available from Enlighten.
Abstract
Angiogenesis, the process whereby tumors develop new blood vessels to facilitate growth and mefastasis, is a pivotal event in tumorigenesis. It is tightly regulated by the VEGF system. Cediranib (AZD2171, Recentin (TM); AsfraZeneca, London, UK) is a novel and potent small-molecule inhibitor of VEGF signaling, with activity against the three VEGF receptors, as well as other targets. This article provides a comprehensive and up-to-date synopsis of all pertinent preclinical and clinical studies detailing this promising new therapy.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Cassidy, Professor James and MacPherson, Professor Iain |
| Authors: | Lindsay, C.R., MacPherson, I.R.J., and Cassidy, J. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
| Journal Name: | Future Oncology |
| ISSN: | 1479-6694 |
University Staff: Request a correction | Enlighten Editors: Update this record
Altmetric
Altmetric